Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | ILK | Q13418 | 13/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514381 | 0.85 | ADORA2A (0.37) | — | |
| SCHEMBL14754763 | 0.85 | ADORA2A (0.37) | — | |
| SCHEMBL31207334 | 0.82 | KHK (0.35) | JAK2ILKSGK1PDPK1 | |
| SCHEMBL31721629 | 0.78 | HPGD (0.46) | JAK2ILKIKBKBAURKAPDPK1 | |
| SCHEMBL14813996 | 0.78 | JAK2 (0.36) | JAK2IKBKBAURKAPDPK1TGFBR1 | |
| SCHEMBL26675449 | 0.75 | JAK2 (0.44) | JAK2AURKAPDPK1TGFBR1AURKB | |
| SCHEMBL14814337 | 0.74 | TYMS (0.39) | — | |
| SCHEMBL23356033 | 0.72 | JAK2 (0.50) | JAK2 | |
| SCHEMBL30791243 | 0.72 | JAK2 (0.50) | JAK2 | |
| SCHEMBL30791283 | 0.71 | OPRM1 (0.38) | ILKSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| EP-3186255-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-05 | — | — | EP | disclosed |
| EP-3186251-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9605008-B2 | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9605008-B2 | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| WO-2015004105-A1 | BENZYL-1H-PYRAZOLO[3,4-B]PYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| EP-2802592-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2751106-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, TYMS, DPYD | JAK2 785/4885ILK 4791/4885SGK1 4391/4885 |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, DPYD, TYMS | JAK2 1697/4885ILK 4670/4885SGK1 4493/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | JAK2 550/4885ILK 4853/4885SGK1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.